HRT and Venous Thrombosis Risk
On this page
Direct answer
Oral hormone replacement therapy roughly doubles the risk of venous thromboembolism, with the excess concentrated in the first year of use and returning toward baseline within about a year of stopping. The mechanism is hepatic: oral oestrogen's first pass through the liver shifts clotting factor synthesis toward coagulation, including acquired activated protein C resistance. Transdermal oestrogen, which bypasses the portal circulation, carries no meaningful VTE excess in observational data and is the preferred route for women with obesity, thrombotic tendency or migraine. Absolute risk in a healthy 50-something remains small, which is why the conversation is about route selection and risk factors, not reflex avoidance of HRT.
What you must remember
- Magnitude: oral oestrogen therapy approximately doubles VTE risk (relative risk around 1.5–2); the absolute excess in women aged 50–59 is small — of the order of one to two extra events per thousand women per year in observational syntheses.
- Timing of risk: highest in the first year of treatment; risk declines toward baseline within roughly a year of cessation — quotable in counselling and viva alike.
- Mechanism: hepatic first pass alters synthesis — increased activated protein C resistance, raised procoagulant factor levels — the reason route determines risk.
- Transdermal advantage: patches, gels and sprays avoid first pass; large observational cohorts (the French E3N data most cited) show no VTE elevation, and UK guidance explicitly prefers transdermal routes in women with BMI above 30 or other thrombotic risk.
- Risk-amplifying states: obesity, prior VTE, thrombophilia, active cancer, immobility and major surgery compound the oral signal — prior VTE is generally a strong relative contraindication to systemic oestrogen therapy.
- Perioperative handling: current guidance does not require routine cessation of HRT before surgery; individualise with the surgical team, applying the same logic as for combined hormonal contraception in higher-risk procedures.
- Regimen nuance: oestrogen drives the risk; oral progestogens add something, while micronised progesterone (or transdermal routes) keeps the combined regimen closer to the oestrogen-alone profile.
- Comparator drugs: tibolone showed no VTE increase in osteoporosis trials; SERMs such as raloxifene increase VTE — the pharmacology family tree examiners like to walk through.
Choosing the route before the first tablet
A 51-year-old with disabling vasomotor symptoms, BMI 34, and a sister with a pulmonary embolism asks for HRT. The answer is built route-first: transdermal oestradiol with micronised progesterone, because her adiposity and family history are exactly the profile where oral therapy's hepatic procoagulant effect buys nothing but risk. Contrast the 49-year-old with early surgical menopause, BMI 22, no risk factors: oral therapy is defensible and convenience may win, provided the first-year vigilance is explained — new leg swelling, chest pain or breathlessness in the first months is an emergency regardless of how benign the tablet seemed. The third conversation is perioperative: she is on transdermal HRT and booked for knee replacement; per current guidance the patch need not stop routinely, and the anaesthetic team's thromboprophylaxis carries the operative risk. What ties the three together is that HRT's VTE story is a route story first and a duration story second — the woman's profile selects the vehicle, and the vehicle largely settles the thrombosis question.
How the exam frames it
Examiners set this topic beside the combined pill: same hepatic logic, different absolute stakes, and the same escape hatch — bypass the portal vein with a transdermal route. The classic stem offers an obese, migrainous woman wanting HRT; the expected answer names transdermal oestradiol and justifies it by first-pass physiology rather than by habit. Follow-up questions chase the first-year concentration of risk, the return to baseline after stopping, and the contrast with raloxifene (bone-protective SERM that still carries VTE risk — pharmacology's elegant trap). Candidates should also hold the reassurance half: for a healthy recently menopausal woman under 60, the absolute VTE risk of oral therapy is small, so refusing HRT wholesale fails the counselling mark every bit as badly as ignoring risk factors. Where the WHI confusion arises, separating venous thrombosis findings (route-dependent) from the breast cancer and cardiovascular headlines (separate debates) shows the discrimination the question is actually testing.
Frequently asked questions
Why does oral HRT raise VTE risk more than transdermal?
Oral oestrogen undergoes hepatic first pass, shifting coagulation protein synthesis — including acquired activated protein C resistance — while transdermal delivery bypasses the liver.
When is VTE risk highest on HRT?
During the first year of treatment, with risk falling toward baseline within about a year of stopping.
Which women should receive transdermal oestrogen preferentially?
Those with obesity (BMI above 30), migraine, venous thrombotic tendency or other VTE risk factors — the route is chosen to neutralise the first-pass effect.
Should HRT be stopped before major surgery?
Current guidance does not mandate routine cessation; decisions are individualised with the surgical and anaesthetic teams alongside standard thromboprophylaxis.
How does raloxifene compare on thrombosis?
Despite its bone-protective SERM profile, raloxifene increases venous thromboembolism risk — a reminder that route and drug class each carry the signal independently.